Clinical trials: Tissue Ischemia
- Condition Tissue Ischemia
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Vascular Disease, Critical Lower Limb Ischemia
Pilot Study of Hemospan® in Patients With Chronic Critical Limb Ischemia
The purpose of this study is to evaluate the effects of Hemospan infusion on vascular reactivity, regional perfusion and oxygenation of ischemic tissue in patients with chronic critical lower limb ischemia.
- Trial name
- NCT00633659
- Testing
- Hemospan (MP4OX), Voluven (HES 130/0.4)
- Where
- Sweden
- Volunteers
- 6 people
- Sponsor
- Sangart
Colon Ischemia, Aortic Aneurysm
Prevention of Colon Ischemia During Aortic Aneurysm (AAA) Repair
Patients undergoing surgery on their Aorta can get ischemia, a lack of blood flow, to their intestines and colon. This is very serious, as 2 out of 3 patients who have this problem die before leaving the hospital.
- Trial name
- NCT00671203
- Testing
- Reestablish colon blood flow
- Where
- 2 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Spectros Corporation
Diabetic Foot Ulcer, Venous Leg Ulcer
Post-Marketing Surveillance of Dehydrated Human Amnion/Chorion Membrane (DHACM) in Non-Ischemic Chronic Wounds
The purpose of this survey is to observe the efficacy and safety of EPIFIX® dehydrated human amnion/chorion membrane (DHACM) for the treatment of intractable diabetic foot ulcers or venous leg ulcers.
- Trial name
- NCT06236750
- Testing
- EPIFIX
- Where
- 5 sites in Japan
- Volunteers
- 75 people
- Sponsor
- MiMedx Group, Inc.
Kawasaki Disease
Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease
The purpose of this trial is to evaluate whether, in Intravenous Immunoglobulin-naïve or refractory patients diagnosed with active Kawasaki disease, administration of canakinumab controls fever and acute phase reactants.
- Trial name
- NCT02980263
- Testing
- Canakinumab
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma, Respiratory Distress Syndrom
NuvOx Expanded Access
NanO₂ is an investigational drug being studied by NuvOx Therapeutics. It has not been approved by the U.S. Food and Drug Administration (FDA) for any use.
- Conditions
- Glioblastoma, Respiratory Distress Syndrom, Ischemic Stroke, Hypoxic Conditions
- Trial name
- NCT07748299
- Testing
- NanO₂
- Sponsor
- NuvOx LLC
Skin Infection, Abscess
Complicated Skin and Skin Structure Infections
The purpose of this study is to demonstrate the non-inferiority of meropenem (Merrem) and imipenem in hospitalised subjects with complicated skin and skin structure infections.
- Conditions
- Skin Infection, Abscess, Cellulitis
- Trial name
- NCT00619710
- Testing
- Meropenem, Imipenem-cilastatin
- Volunteers
- 1,000 people
- Sponsor
- Pfizer